KOSDAQBiotech & Pharma237690

ST Pharm

₩70,200▼ 1.13%2026-11-18 close
Market Cap
₩1.5T
Turnover
₩2.9B
Volume
40K
Shares out.
20.9M
PER
24.1×
PBR
2.4×
EPS
₩2,950
Dividend Yield
0.70%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩500 per share · Prices as of the 2026-11-18 close

01

Report overview

Oligo Orders Rise While Net Income Falls at ST Pharm

ST Pharm's oligonucleotide CDMO orders and commercial sales are growing, but net income attributable to controlling shareholders fell 94.2% in 3Q 2026, which the company attributes mainly to non-operating currency effects.

  1. 1

    On a DART-filed basis, 2025 revenue was KRW 331.7 billion and operating profit was KRW 54.9 billion, the largest year of 2022 to 2025.

  2. 2

    In 3Q 2026, revenue rose 19.1% year on year to KRW 97.6 billion and operating profit rose 6.6% to KRW 15.7 billion, while net income attributable to controlling shareholders fell 94.2% to KRW 1.02 billion.

  3. 3

    The oligonucleotide order backlog was about USD 270 million at end-September 2026, and the KRW 91.3 billion contract signed in September 2026 is the largest single oligo supply contract in the company's history.

  4. 4

    A second expansion phase at the No. 2 oligo building is due to be decided within 2026, with a target of up to 14 mol of annual capacity by 2029.

  5. 5

    Net income attributable to controlling shareholders has declined for three straight quarters from 1Q to 3Q 2026, and the 4Q 2025 figure accounts for more than half of the KRW 60.2 billion four-quarter total.

02

Business structure

ST Pharm is a contract development and manufacturing organization (CDMO) whose core business is oligonucleotide (oligo) active pharmaceutical ingredients. Oligo sales in 3Q 2026 were KRW 69.0 billion, up 0.6% year on year, and commercial project sales of KRW 49.7 billion made up about 72% of oligo sales.

Small molecule sales were reported at KRW 11.6 billion on the company's results summary, while the product-level sales table in the same disclosure cited a different figure. Sales of CRO and other subsidiaries were KRW 8.8 billion, down 5.6% year on year, while standalone 3Q sales of KRW 88.8 billion rose 22.3%.

In mRNA, the company won two new projects, including a personalized cancer vaccine, and recorded revenue from clinical projects using its in-house SmartCap and lipid nanoparticle (LNP) technologies.

As of end-September 2026, the oligo backlog was about USD 270 million, of which about 78% was commercial projects, and the small molecule backlog was about USD 40 million.

The company won 12 new oligo projects in 2026, eight in the first half and four in 3Q, and indications have broadened to obesity, neurological, metabolic and autoimmune diseases. It also won antibody-oligonucleotide conjugate (AOC) projects, adding conjugation-based CDMO work.

The customer for the KRW 91.3 billion contract signed in September 2026 has not been disclosed under a confidentiality clause. On competition, the company says it currently holds top-three oligo CDMO capacity and aims to move into the top two after its second expansion is completed.

The company plans to focus on new CDMO orders and broader therapeutic areas, building on stable supply from existing commercial projects.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩81.9B₩14.7B18.0%
2025Q4₩129.1B₩26.3B20.3%
2026Q1₩67B₩11.5B17.2%
2026Q2₩108.5B₩18.3B16.9%
2026Q3₩97.6B₩15.7B16.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩249.3B₩17.9B₩17.5B7.2%5.2%67.3%
2023₩285B₩33.5B₩19.6B11.8%5.1%74.6%
2024₩273.8B₩27.7B₩34.7B10.1%6.9%43.5%
2025₩331.7B₩54.9B₩55B16.6%9.3%32.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a DART-filed basis, annual revenue rose from KRW 249.3 billion in 2022 to KRW 285 billion in 2023 (up 14.3%), fell to KRW 273.8 billion in 2024 (down 3.9%), and then reached KRW 331.7 billion in 2025 (up 21.2%), the largest year of 2022 to 2025.

Operating profit went from KRW 17.9 billion in 2022 and KRW 33.5 billion in 2023 to KRW 27.7 billion in 2024 and KRW 54.9 billion in 2025, and the 2025 figure grew 98.4% year on year, well ahead of revenue growth.

The operating margin was 7.2% in 2022, 11.8% in 2023, 10.1% in 2024 and 16.6% in 2025, dipping in 2024 before reaching the highest level of the four years in 2025.

Net income attributable to controlling shareholders was KRW 17.5 billion in 2022, KRW 19.6 billion in 2023, KRW 34.7 billion in 2024 and KRW 55 billion in 2025, rising three years in a row from 2023 through 2025.

Net income including non-controlling interests was KRW 54.6 billion in 2025, a different figure from the controlling-shareholder number.

The balance sheet strengthened: the debt-to-equity ratio fell from 67.3% in 2022 to 32.0% in 2025, with total equity of KRW 593 billion, equity attributable to controlling shareholders of KRW 593.4 billion and total liabilities of KRW 189.6 billion at end-2025.

Operating cash flow was KRW 7.03 billion in 2022, KRW 1.3 billion in 2023, KRW 109.5 billion in 2024 and KRW 14 billion in 2025, so 2025 cash generation fell sharply from 2024 despite higher profit.

Quarterly results peaked in 4Q 2025, with revenue of KRW 129.1 billion, operating profit of KRW 26.3 billion and net income attributable to controlling shareholders of KRW 31 billion, up 57.6%, 78.4% and 76.1% from the prior quarter.

Revenue then fell to KRW 67 billion in 1Q 2026 (down 48.1% quarter on quarter), recovered to KRW 108.5 billion in 2Q 2026 (up 62.0%), and dropped to KRW 97.6 billion in 3Q 2026 (down 10.1%).

In 3Q 2026, operating profit rose 6.6% year on year to KRW 15.7 billion, but net income attributable to controlling shareholders fell 94.2% to KRW 1.02 billion. The company attributed the decline to non-operating items, including foreign exchange losses and foreign currency translation losses from the weaker won.

The operating margin fell from about 18.0% a year earlier to 16.1%, which the company linked to the weaker currency and a higher mix of low-margin generic products.

Over the last four quarters, net income attributable to controlling shareholders totaled KRW 60.2 billion, and 4Q 2025 alone contributed KRW 31 billion, more than half of that total, so recent profit depends heavily on a single quarter.

05

Industry analysis

Industry sources note that oligonucleotide therapies need sharply rising volumes of raw material as development moves toward commercial stage. Analysts say that as RNA therapies expand from rare diseases into chronic conditions, both supply volumes and contract sizes for oligo active ingredients are growing.

Commercial volumes run at larger production scale than clinical material and are more likely to recur, so demand for oligo CDMO work is shifting its weight from clinical to commercial supply.

Analysts saw the KRW 91.3 billion contract signed in September 2026 as added volume tied to an existing commercial product's indication expansion, and some in the industry have suggested it may relate to a commercial product of the US biotech Ionis.

Supply-chain diversification by global pharma and biotech companies, driven by US regulatory moves against Chinese biotech firms, could shift part of the volume that Chinese CDMOs handle to other regions.

Companies with commercial manufacturing experience and large-scale oligo facilities are seen as well placed to capture such volume. The company says it currently holds top-three oligo CDMO capacity by its own assessment, and whether it moves into the top two will be judged after the second expansion is complete.

Currency also matters for earnings. In 3Q 2026, the weaker won produced foreign exchange and translation losses that cut net income and also weighed on the operating margin.

06

Outlook

The company spent about KRW 118.2 billion on the No. 2 oligo building and its first expansion phase, and is planning a second phase that would add production lines on the remaining two floors.

It targets completion of the second phase by 2029, which would raise annual oligo capacity to up to 14 mol, roughly 2.3 to 7 tons. The company has said it will finalize the scope, line layout and investment approach within 2026.

Reports say it is weighing its own cash and policy funds such as the National Growth Fund over rights offerings or convertible bonds, and cash and cash equivalents were about KRW 30.5 billion at end-2025.

On the outlook side, Daishin Securities projected in a September 2026 report revenue of KRW 411 billion and operating profit of KRW 71 billion for 2026, and revenue of KRW 521 billion and operating profit of KRW 91 billion for 2027.

Reaching the 2026 forecast would require 4Q 2026 revenue to rise well above the KRW 97.6 billion reported for 3Q. The same report expected the KRW 91.3 billion contract signed in September 2026 to be reflected mainly in 2027 results. That contract runs from September 2026 to November 2027.

The company had won 12 new oligo projects as of end-September 2026, and it has presented expansion into small molecules, mRNA and AOC as its next growth steps. The key variables for the outlook are the size and funding of the second expansion and whether commercial-stage volumes keep recurring.

07

Valuation

PER
24.1×
PBR
2.4×
ROE
10.3%
EPS
₩2,950
BPS
₩29,337
Dividend per share
₩500

A price-to-earnings reading based on net income attributable to controlling shareholders is affected by the drop to KRW 1.02 billion in 3Q 2026, so the picture differs between a trailing four-quarter basis, which totals KRW 60.2 billion, and an annual basis.

In the four-quarter total, 4Q 2025 contributed KRW 31 billion, more than half, so the concentration of profit in that quarter shapes how the multiple reads. Operating profit rose year on year in 3Q 2026, so an operating view that excludes currency effects points in a different direction from the net income multiple.

The price-to-book ratio sits well above 1x on equity attributable to shareholders, and the market capitalization is more than twice total equity.

Even after the 2025 profit recovery, the asset-based premium remains, and analysts read it in two ways: as growth expectations already priced in, or as a premium that reflects concern about earnings volatility. The dividend yield is low, so dividends contribute only modestly to shareholder returns.

If operating profit reaches the KRW 91 billion in Daishin's 2027 forecast, it would be well above the KRW 71 billion in its 2026 forecast, and the multiple read would shift accordingly.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Largest single contract on record

After contracts of KRW 82.5 billion in January and KRW 89.7 billion in March, a KRW 91.3 billion contract in September pushed the 2026 cumulative large oligo orders past KRW 260 billion. The September contract is the largest single oligo supply contract in the company's history and runs through November 2027. Daishin Securities said it expected the volume to be reflected mainly in 2027 results.

Rising share of commercial volume

Commercial projects generated KRW 49.7 billion of the KRW 69.0 billion in oligo sales in 3Q 2026, about 72%. Commercial projects make up about 78% of the roughly USD 270 million oligo backlog. Analysts note that commercial volumes run at larger scale than clinical material and tend to recur.

Second expansion plan to add capacity

After completing the first phase, the company plans a second phase that would lift annual oligo capacity to as much as 14 mol by 2029. It has said it will confirm the second-phase plan within 2026. The company has stated that the expansion is aimed at moving into the top two oligo CDMO positions.

09

Bear factors

Sharp drop in 3Q net income

Net income attributable to controlling shareholders fell 94.2% year on year to KRW 1.02 billion in 3Q 2026. The company cited foreign exchange and translation losses from the weaker won, but the controlling-shareholder figure has declined for three consecutive quarters from 1Q to 3Q 2026. The composition of non-operating items will be a checkpoint in the next periodic report.

Lower margins from low-margin products

The operating margin fell to 16.1% in 3Q 2026 from about 18.0% a year earlier. The company cited the weaker won and a higher share of low-margin products such as generics. Whether the margin trend continues from 16.6% in 2025 can be checked in the 2026 annual report.

Expansion spending and cash generation

About KRW 118.2 billion went into the No. 2 building and its first expansion phase, and cash and equivalents were about KRW 30.5 billion at end-2025. Operating cash flow fell to KRW 14 billion in 2025 from KRW 109.5 billion in 2024.

The company reportedly prefers its own cash and policy funds for the second phase, but market concern about dilution has also been reported.

10

Risk factors

Currency risk

In 3Q 2026, a weaker won produced foreign exchange and translation losses that sharply cut net income attributable to controlling shareholders. The company said the exchange rate also affects its operating margin. Because contract values are denominated in dollars, currency swings can add to quarterly earnings volatility.

Project timing and contract dependence

At end-2025, the company counted 20 oligo projects in preclinical or clinical stages and five in commercial stage, and said projects expected to receive approval could change with clinical progress. As single contracts grow larger, a change in contract timing or customer schedule could weigh more on quarterly results. Many customers are not disclosed, which makes schedule changes harder to track from outside.

Execution and utilization risk

The second expansion is planned in stages through 2029, so the timing of capacity coming online and the payback period remain uncertain. The semi-annual report put the oligo building utilization at 75.4%, a weighted average across both buildings that does not allow easy calculation of spare capacity by line. If the expansion decision slips, production support for large orders could also be constrained.

11

What to watch next

  1. By end-2026

    Whether the second expansion's line scope, investment size and funding method are confirmed, and whether the target of up to 14 mol of capacity changes.

  2. During 1Q 2027

    The preliminary full-year and 4Q 2026 results, which are normally released in early year. Whether 4Q revenue approaches the forecast level and whether controlling-shareholder net income recovers are the points to check.

  3. By March 31, 2027

    Filing of the 2026 annual report, which will confirm full-year operating margin, net income attributable to controlling shareholders, the composition of non-operating items and the year-end backlog.

  4. November 2027

    End of the contract period for the KRW 91.3 billion oligo supply agreement, when the extent of revenue recognition and any follow-on orders become visible.

12

Overall view

ST Pharm is a company whose oligo CDMO orders and commercial volumes are growing together. On a DART-filed basis, 2025 revenue of KRW 331.7 billion and operating profit of KRW 54.9 billion were the largest figures of 2022 to 2025, and the debt-to-equity ratio fell from 67.3% in 2022 to 32.0% in 2025.

In 3Q 2026, revenue of KRW 97.6 billion and operating profit of KRW 15.7 billion were both higher than a year earlier, but net income attributable to controlling shareholders was only KRW 1.02 billion because of non-operating currency items.

Growth evidence cited includes the KRW 91.3 billion single contract in 2026, an oligo backlog of about USD 270 million, and the second expansion plan.

Weak points include the sharp drop in 3Q net income, a lower operating margin as low-margin products grow, the fall in 2025 operating cash flow, and the funding burden of large expansion spending.

The next checkpoints are the second-phase expansion decision due within 2026, the 2026 annual report due by March 31, 2027 with its full-year operating margin and net income, and whether the KRW 91.3 billion contract is reflected in results through its November 2027 end.

This report is provided for information only and does not include an investment opinion, rating or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. monews.co.kr
  2. leadeconomy.co.kr
  3. kormedi.com
  4. thepowernews.co.kr
  5. ziksir.com
  6. etnews.com
  7. newspim.com
  8. dailian.co.kr
  9. asiatime.co.kr
  10. lawissue.co.kr
  11. press9.kr
  12. theviewers.co.kr
  13. dealsite.co.kr
  14. thebionews.net
  15. medipana.com
  16. sisajournal-e.com
  17. dailyinvest.kr
  18. m.sedaily.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis